[6]Ishak KG. Pathologic features of chronic hepatitis. A review and
update. Am J Clin Pathol, 2000, 113: 40-55.
[7]Scheuer PJ, Standish RA, Dhillon AP. Scoring of chronic hepatitis. Clin Liver Dis, 2002, 6:
335-347.
[8]Chevallier M, Guerret S, Chossegros P, et al. A histological semiquantitative scoring system
for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with
morphometric studies. Hepatology, 1994, 20: 349-355.
[9]Shanghai Cooperative Group of Hepatic Fibrosis Project. Preliminary appraisal of diagnostic
value of CT and MRI in hepatic fibrosis. Shanghai Yixue, 2002, 25: 210-213.
上海市肝纤维化课题协作组.肝纤维化CT、MR诊断初步探讨.上海医学,2002,25:210-213.
[10]Bissell DM. Assessing fibrosis without a liver biopsy: are we there yet? Gastroenterology,
2004, 127: 1847-1849.
[11]Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver
fibrosis: a cohort study. Gastroenterology, 2004, 127: 1704-1713.
[12]Kelleher TB, Mehta SH, Bhaskar R, et al. Prediction of hepatic fibrosis in HIV/HCV
co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol, 2005, 43: 78-84.
[13]Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive patients
with chronic hepatitis B by a noninvasive model. Hepatology, 2005, 42: 1437-1445.
[14]Zeng MD, Lu LG, Mao YM. Assessments of diagnostic methods for hepatic fibrosis. Ganzang,
2006, 11: 181-183.
曾民德, 陆伦根,茅益民.
肝纤维化的诊断方法及其评估（下）.肝脏,2006,11:181-183.
[15]Zhang WS, Wang BE, Wang TL, et al. Noninvasive assessment of liver fibrosis in chronic
hepatitis B using a predictive model. Zhonghua Ganzangbing Zazhi, 2006, 14: 169-173.
张文胜,王宝恩,王泰龄,等.慢性乙型肝炎肝纤维化无创性诊断模型的建立.中华肝脏病杂志,2006,14:169-173.
[16]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical
Association. The guideline of prevention and treatment fon chronic hepatitis B. Zhonghua
Ganzangbing Zazhi, 2005, 13: 881-891.
中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南.中华肝脏病杂志,2005,13:881-891.
[17]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical
Association. The guideline of prevention and treatment for chronic hepatitis C. Zhonghua
Ganzangbing Zazhi, 2004,12: 194-198.
中华医学会肝病学分会、中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南.中华肝脏病杂志,2004,12:194-198.
[18]Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease
Association. Guidelines for diagnostis and treatment of alcoholic liver diseases. Zhonghua
Ganzangbing Zazhi, 2006, 14: 164-166.
中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南.中华肝脏病杂志,2006,14:164-166.
[19]Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease
Association. Guidelines for diagnostis and treatment of nonalcoholic fatty liver diseases.
Zhonghua Ganzangbing Zazhi, 2006, 14: 161-163.
中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南.中华肝脏病杂志,2006,14:161-163.
[20]National Criterion. UDC-GB15977. Diagnostic Criteria for Schistosomiasis joponico and Its
Guidelines for Control. 1995
中华人民共和国国家标准.UDC-GB15977.日本血吸虫病诊断标准和处理标准.1995.
[21]Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive patients
with chronic hepatitis B by a noninvasive model. World J Gastroenterol, 2005, 11: 2892-2899.
[22]Zhou GD, Li WS, Zhao JG, et al. Clinical pathological study on the mechanism of effect of
Fufangbiejiaruanganpian in treatment of liver fibrosis. Jiefangjun Yixue Zazhi, 2004, 29:
563-564.
周光德,李文淑,赵景民,等.复方鳖甲软肝片抗肝纤维化机制的临床病理研究.解放军医学杂志,2004,29:563-564.
[23]Hu YY, Liu P, Liu C, et al. Dahuang Zhechong Pills(DHZC) in treatment of chronic liver
injury and liver fibrosis. Zhongxiyi Jiehe Ganbing Zazhi, 1995, 5: 28-30.
胡义扬,刘平,刘成,等.大黄
虫丸抗慢性肝损伤及肝纤维化作用的实验研究,中西医结合肝病杂志,1995,5:28-30.
[24]Sun KW, Chen X, Liu WS, et al. Experimental study of dahuang zhechong pills(DHZC) in
treatment of immunological liver fibrosis in rast. Zhongguo Zhongyao Zazhi, 1998, 23: 497-499.
|
孙克伟,陈翔,刘伟士,等.大黄
虫丸抗大鼠免疫性肝纤维化研究.中国中药杂志,1998,23:497-499.
[25]Liu P, Liu C, Chen GC, et al. Effect of fuzheng huayu 319 recipe on serological parameters
of fibrosis in treating chronic hepatitis B. Zhongguo Zhongxiyi Jiehe Zazhi, 1996, 16: 588-592.
刘平,刘成,陈高潮,等.扶正化瘀319方治疗慢性乙型肝炎及其对纤维化血清学指标的影响.中国中西医结合杂志,1996,16:588-592.
[26]Kuang WH, Li JH. Effect of Biejia Jian in preventing rat hepatic fibrosis. Zhongyao Xinyao
Yu Linchuang Yaoli, 2004, 15: 314-317.
邝卫红,李建华.鳖甲煎汤抗大鼠肝纤维化作用.中药新药与临床药理,2004,15:314-317.
[27]Zhao ZY, Zhong QP, Zhu FY, et al. Clinical observation of Biejiajian wan on treating 40
liver fibrosis patient. Ganzang, 2001, 6: 105-106.
赵治友,钟庆平,朱飞燕,等.古方鳖甲煎丸抗肝纤维化40例疗效观察.肝脏,2001,6:105-106.
[28]Shimizu I. Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis
and carcinoma. J Gastroenterol Hepatol, 2000, 15 Suppl:D84-90.
[29]Yang LM, Xu KC, Zhao YL, et al. Clinic-pathological study on therapeutic efficacy of
Qianggan capsule for hepatic fibrosis of chronic hepatitis B. Weichangbingxue He Ganbingxue
Zazhi, 2001, 10: 247-249.
杨柳明,徐克成,赵延龙,等.强肝胶囊治疗慢性乙型肝炎肝纤维化的临床病理研究.胃肠病学和肝病学杂志,2001,10:247-249.
[30]Yin SS, Wang BE, Wang TL, et al. The effect of Cpd 861 on chronic hepatitis B related
fibrosis and early cirrhosis: a randomized, double blind, placebo controlled clinical trial.
Zhonghua Ganzangbing Zazhi, 2004, 12: 467-470.
尹珊珊,王宝恩,王泰龄,等.复方861治疗慢性乙型肝炎肝纤维化与早期肝硬化的临床研究.中华肝脏病杂志,2004,l2:467-470.
[31]Cheng ML, Ding YS, Luo YF, et al. Clinical study of Han-Dan-Bi-Tuo on treating chronic
active hepatitis and liver fibrosis. Zhongguo Zhongxiyi Jiehe Zazhi, 1996, 16: 431-432.
程明亮,丁一生,罗永芳,等.汉丹必妥治疗慢性活动性肝炎肝纤维化的临床研究.中国中西医结合杂志,1996,16:431-432.
[32]Weng HL, Cai WM, Wang BE, et al. Clinical study of anti-hepatic fibrosis effect of IFN-γ in
patients with chronic hepatitis B. Zhonghua Yixue Zazhi, 2003, 83: 943-947.
翁红雷,蔡卫民,王宝恩,等.重组干扰素γ治疗慢性乙型肝炎肝纤维化临床研究.中华医学杂志,2003,83:943-947.
[33]Du XF, Weng HL, Cai WM. Histological changes in 20 hepatic fibrosis patients with chronic
hepatitis B after recombinant human interferon-γ treatment. Zhonghua Ganzangbing Zazhi, 2001,
9: 273-275.
杜心芳,翁红雷,蔡卫民.IFN-γ治疗20例慢性乙型肝炎肝纤维化患者肝组织学变化.中华肝脏病杂志,2001,9:273-275.
[34]Mao YM, Zeng MD, Lu LG, et al. Caspsule oxymatrine in the treatment of liver fibrosis in
patients with chronic virus hepatitis: A randomized, double bline, placebo-controlled,
multicenter clinical study(II).Ganzang, 2002, 7: 222-225.
茅益民,曾民德,陆伦根,等.氧化苦参碱胶囊治疗慢性病毒性肝炎肝纤维化的随机、双盲、安慰剂对照多中心临床研究(Ⅱ).肝脏,2002,7:222-225.
附: 编写说明
本《指南》旨在建立我国中西医结合诊断与治疗肝纤维化疾病的临床共识，为从事肝脏疾病防治的中医、中西医结合临床医师提供指导性意见，而不是强制性标准。因此，临床医生在针对某一具体患者时，应充分了解本病的最佳临床证据和现有医疗资源，并在全面考虑患者的具体病情及其意愿的基础上，根据自己的知识和经验，制定合理的诊疗方案。本指南将根据研究进展和需要不断更新和完善。
本《指南》所推荐药物的证据质量要求：
新药：经国家药品监督管理局批准，有明确的肝纤维化适应证，并有公开发表的具有达到统计学要求的肝组织学评价的抗肝纤维化临床研究资料。
经典方药：指出自中医学四大经典著作的方剂，并且具有肝病应用的临床报道，有抗肝纤维化作用的实验研究发表资料。
经验方：发表的研究资料中有肝组织学药效评价，证据等级Ⅱ-1级以上。
药物名称与剂量：根据中华人民共和国药典2005年版，标注名称、剂量、应用范围，剂量单位为g。经典方根据原方剂量及古今度量衡折算法换算为g。
《指南》涉及的名词术语与药物，参考国家药品监督管理局安全监管司国家药品监督管理局药品评价中心编写的“国家基本药物-西药”（2002年第2版）、
“国家基本药物-中成药”（2002年第1版），以及“中医大辞典“（2005年第2版）和“中医药学名词审定委员会编写的“中医药学名词-2004”（2005年第1版）等资料。 |
